Andrew Rogers
Johnson City, TNNPI 1336706183
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,618 of the $13,858 with a category attached, or 62.2%. Idorsia Pharmaceuticals US Inc accounts for 69.8% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $9,911 and has fallen 95.9% since, to $407 in 2025.
Across 270 payments — averaging $51.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Idorsia Pharmaceuticals US Inc$10K
- Novo Nordisk$2K
- AbbVie$549
- Lilly USA, LLC$344
- Corcept Therapeutics$328
- Supernus Pharmaceuticals, Inc.$177
- plus $702 from 13 others
What the payments were for
- Speaking & faculty fees$8,61862%
- Travel & lodging$4233%
- Food & beverage$4,80635%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Idorsia Pharmaceuticals US Inc | 32 | $9,672 |
| Novo Nordisk | 147 | $2,088 |
| AbbVie(2 entities) | 19 | $549 |
| Lilly USA, LLC | 18 | $344 |
| Corcept Therapeutics | 15 | $328 |
| Supernus Pharmaceuticals, Inc. | 8 | $177 |
| Pfizer | 6 | $106 |
| Merz North America, Inc. | 1 | $98 |
| Revance Therapeutics, Inc. | 3 | $84 |
| Biohaven Pharmaceuticals, Inc. | 2 | $76 |
| Galderma Laboratories, L.p. | 2 | $71 |
| Clarus Therapeutics Inc. | 5 | $61 |
| Acella Pharmaceuticals, LLC | 3 | $58 |
| AstraZeneca | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Mannkind Corporation | 2 | $24 |
| Insulet Corporation | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Boston Scientific | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 17 | $16,396 |
| MounjaroTirzepatide | 14 | $13,841 |
| Armour ThyroidThyroid,pork | 23 | $605 |
| Minoxidil | 11 | $194 |
| Pantoprazole Sodium | 20 | $172 |
| Ramipril | 11 | $105 |
| Losartan Potassium | 17 | $89 |
| Levothyroxine Sodium | 19 | $62 |
| Meloxicam | 16 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,088 | $16,39617 claims |
| Lilly USA, LLCMounjaro | $344 | $13,84114 claims |
| AbbVieArmour Thyroid | $549 | $60523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Tennesseeon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.